KDR and hepatocellular carcinoma: Despite the recent advances in systemic therapy for unresectable HCC, patients who progress on first-line multikinase inhibitors, namely sorafenib [which targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR-β) and rapidly accelerated fibrosarcoma (RAF) kinases] [6,7,8] and lenvatinib (which targets VEGFR1, VEGFR2 and VEGFR3, PDGFR alpha, fibroblast growth factor receptor (FGFR) and KIT and RET tyrosine kinases) [9,10,11,12,13], have limited options [5,14].